Xiaomeng Zhang
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery and development of the preclinical candidate (SH-1092), a potent third generation EGFR inhibitor for the treatment of NSCLC.
Journal: Bioorganic chemistry
Published: November 07, 2025
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 13, 2022
Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma.
Journal: Journal of medicinal chemistry
Published: May 31, 2022
Dynamics-Based Discovery of Novel, Potent Benzoic Acid Derivatives as Orally Bioavailable Selective Estrogen Receptor Degraders for ERα+ Breast Cancer.
Journal: Journal of medicinal chemistry
Published: May 31, 2021
SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
Journal: Frontiers in pharmacology
Published: February 07, 2021
Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
Journal: Bioorganic & medicinal chemistry letters
Published: March 24, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026